Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Patients with heart failure (HF) and atrial fibrillation (AF) have higher circulating levels of NT-proBNP (N-terminal pro-B-type natriuretic peptide) than HF patients without AF. There is uncertainty about the prognostic importance of a given concentration of NT-proBNP in HF patients with and without AF. We investigated this question in a large cohort of patients with HF and reduced ejection fraction.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Circ Heart Fail

Title: Circulation. Heart failure

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1941-3297

ISSN (Print): 1941-3289

Publication date (Electronic): Oct 2017

Volume: 10

Issue: 10

Affiliations

[1 ] From the BHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (S.L.K., P.S.J., U.M.M., R.R., J.J.V.M.); Department of Cardiology, Rigshospitalet University Hospital, Copenhagen, Denmark (S.L.K., U.M.M., R.R., L.K.); The Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus (W.TA.); Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.D., S.D.S.); Stavanger University Hospital, Stavanger, and Department of Clinical Science, the Institute of Internal Medicine, University of Bergen, Norway (K.D.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Medical University of South Carolina and RHJ Department of Veterans Administration Medical Center, Charleston (M.R.Z.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom (K.S.); and Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.).

[2 ] From the BHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (S.L.K., P.S.J., U.M.M., R.R., J.J.V.M.); Department of Cardiology, Rigshospitalet University Hospital, Copenhagen, Denmark (S.L.K., U.M.M., R.R., L.K.); The Division of Cardiovascular Medicine, Davis Heart and Lung Research Institute, Ohio State University, Columbus (W.TA.); Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA (A.D., S.D.S.); Stavanger University Hospital, Stavanger, and Department of Clinical Science, the Institute of Internal Medicine, University of Bergen, Norway (K.D.); Institut de Cardiologie de Montréal, Université de Montréal, Canada (J.L.R.); Medical University of South Carolina and RHJ Department of Veterans Administration Medical Center, Charleston (M.R.Z.); Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden (K.S.); Faculty of Medicine, National Heart and Lung Institute, Imperial College, London, United Kingdom (K.S.); and Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.). john.mcmurray@glasgow.ac.uk.

Article

Publisher Item ID: CIRCHEARTFAILURE.117.004409

DOI: 10.1161/CIRCHEARTFAILURE.117.004409

PubMed ID: 29018174

SO-VID: 3c7bb786-2edf-43c8-afae-1adfd274cc52

History

Keywords: natriuretic peptide, brain,heart failure,atrial fibrillation

Data availability:

Keywords: natriuretic peptide, brain, heart failure, atrial fibrillation

Comments

Comment on this article

scite_

Cited by 26

See all cited by